OpGen (NASDAQ:OPGN) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Stock Performance

Shares of OPGN opened at $3.03 on Friday. OpGen has a twelve month low of $1.65 and a twelve month high of $38.40. The firm’s 50-day moving average is $3.03 and its two-hundred day moving average is $4.24.

Hedge Funds Weigh In On OpGen

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp purchased a new stake in OpGen, Inc. (NASDAQ:OPGN) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned about 2.63% of OpGen at the end of the most recent reporting period. Institutional investors and hedge funds own 2.68% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.